Nitrumon en es it fr

Nitrumon Brand names, Nitrumon Analogs

Nitrumon Brand Names Mixture

  • No information avaliable

Nitrumon Chemical_Formula


Nitrumon RX_link

Nitrumon fda sheet

Nitrumon msds (material safety sheet)

Nitrumon MSDS

Nitrumon Synthesis Reference

Johnston TP et al. J Med Chem 122:669-681(1963).

Nitrumon Molecular Weight

214.049 g/mol

Nitrumon Melting Point

31 oC

Nitrumon H2O Solubility

< 0.1 g/100 mL at 18 °C

Nitrumon State


Nitrumon LogP


Nitrumon Dosage Forms

Powder for solution; Wafer

Nitrumon Indication

For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.

Nitrumon Pharmacology

Carmustine is one of the nitrosoureas indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in treatment of brain tumors, multiple myeloma, Hodgkin's disease, and non-Hodgkin's lymphomas. Although it is generally agreed that carmustine alkylates DNA and RNA, it is not cross resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins.

Nitrumon Absorption

5 to 28% bioavailability

Nitrumon side effects and Toxicity

The oral LD50s in rat and mouse are 20 mg/kg and 45 mg/kg, respectively. Side effects include leukopenia, thrombocytopenia, nausea. Toxic effects include pulmonary fibrosis (20-0%) and bone marrow toxicity.

Nitrumon Patient Information

No information avaliable

Nitrumon Organisms Affected

Humans and other mammals